spacer
home > ebr > Spring 2018
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2018

   
Text
PDF
Editor’s Letter

EBR Editor Dr Deborah O’Neil looks at the potential of cannabis use in healthcare, relating it to topics discussed in this edition.
 
view
download pdf
bullet
BioResearch and Innovation
Future Migraine Treatment

Getting Ahead

Recent advancements in biopharmaceuticals in the area of migraine studies have the potential to bring relief to many individuals. Professor Dr Uwe Reuter at Charité Universitätsmedizin explains how.
 
view
download pdf
bullet
Discovery Technology
Immunogenicity and the Development of Biopharmaceuticals

Sudden Impact


Dr Gary Bembridge and Dr Karen Hills at Abzena comment on the approaches that can be taken in the pre-clinical stages to reduce the effects of immunogenicity on patient experience and product success.
 
view
download pdf
Technologies for Targeting the Cell Surfaceome

Scratching the Surface

Dr Maria Pavlou and Dr Paul Helbling at Dualsystems Biotech suggest that developing methodologies to study the surfaceome is crucial to cellular differentiation advancement, resulting in the creation of new treatments.
 
view
download pdf
The Potential of Bacterial Lysates

From Pharma to Beauty

Bacterial lysates can be used in many applications, especially disease protection, due to their ability to act as an immune stimulant. Dr Christian Sanchez and Maxence de Villemeur at Lallemand Pharma analyse further.
 
view
download pdf
bullet
Legal, Regulatory and Public Policy
Regulatory Challenges

Rules for Success

Dr William Bridges at Regulatory Affairs Professionals Society believes that regulatory aspects can propel an organisation towards success by enforcing policies, compliance, and good practices.
 
view
download pdf
bullet
INDUSTRY DYNAMICS
In Brief

Precision Healthcare

EBRs Industry Advisor, Emile Bellott, surveys the potential ramifications of Amazon’s recently announced healthcare services, which aims to be an affordable solution for consumers.
 
view
download pdf
bullet
CELL-BASED RESEARCH
Q&A: Albumin in Cell Culture

Therapy at Work

EBR asked Dr Daniel Shelly at Albumedix about cell therapy, looking specifically at the use of albumin in cell culture and current treatments, as well as the challenges that have to be overcome.


 
view
download pdf
Animal Component-Free Media Formulations

Blood-Free Matters

Dr Randall Alfano at InVitria Product Development describes the use of fetal bovine serum in the advancement of in vitro biology, but suggests that a serum-free media formulation could enhance safety and reproducibility.
 
view
download pdf
Customised Viral Engineering

Proactive Progress

Customised viral engineering can create safe and effective adeno-associated virus gene delivery, reveal Tatjana Buchholz at PlasmidFactory, Dr Carl J Christel at Sirion Biotech, and Dr Hüseyin Besir at PROGEN Biotechnik.


 
view
download pdf
bullet
Mass Spectrometry
Capturing Protein-Defining Information

Redefining Proteomics

Mass spectrometry can find the proteins that make a sample, but Dr Christian Loch at AVMBioMed highlights the extract-based functional assay technique.
 
view
download pdf
bullet
Biomarkers and Personalised Medicine
Personalised Medicine

At a Glance

Is society ready for personalised medicines and its ethical implications? Guenther Proll at Biametrics has the answer and examines the progress of its sequencing.
 
view
download pdf
Precision Medicine

Beyond the Genome

Dr Jason Mellad at Cambridge Epigenetix states that collaboration is key to realising the potential of epigenetic research, and successive innovations and applications can aid the industry’s understanding of this.
 
view
download pdf
Biomarkers in Oncology

Tomorrow’s Treatments

Tarquin Edwards at Peckwater PR claims that personalising cancer care and using biomarkers and personalised medicine in oncology is being supported by Big Pharma, thus transforming cancer treatments.
 
view
download pdf
bullet
Biobanks and Strategic Processes
Biobanks and Strategic Processes

Data Swap

Colin Thurston at Brooks Life Sciences recommends adopting three key biobank technology solutions to make research more stratified and effective, thereby aiding researchers.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement